Drugs / Polysaccharide Krestin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01685489 | May 2013 → ? | prostate neoplasm | Bastyr University | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polysaccharide Krestin | “This is a phase 1b study that follows a 3+3 dose escalation design and consists of a 21-day lead-in period of oral Polysaccharide Krestin (PSK)/placebo (study drug) alone...” NCT01685489 ↗ |
| Known as | PSK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01685489 ↗ |
| Route | Oral | “oral PSK alone” NCT01685489 ↗ |